The next Nim­bus? Head of bil­lion-dol­lar drug pro­gram launch­es HotSpot with $45M A round

Re­mem­ber that bil­lion-dol­lar drug idea that got lit­tle Nim­bus on Gilead’s radar back in 2016? Well, the folks be­hind that drug are build­ing a whole plat­form on a sim­i­lar con­cept. And they’re not just tack­ling NASH, but a whole line­up of pre­vi­ous­ly un­drug­gable tar­gets.

The ven­ture, called HotSpot Ther­a­peu­tics, came out Tues­day with news that it’s be­ing backed by Nim­bus’ lead in­vestor — At­las Ven­ture — in a $45 mil­lion Se­ries A round co-led by Sofinno­va.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.